WO2007027353A2 - Detection de proteases secretees a partir de micro-organismes pathogenes - Google Patents

Detection de proteases secretees a partir de micro-organismes pathogenes Download PDF

Info

Publication number
WO2007027353A2
WO2007027353A2 PCT/US2006/030107 US2006030107W WO2007027353A2 WO 2007027353 A2 WO2007027353 A2 WO 2007027353A2 US 2006030107 W US2006030107 W US 2006030107W WO 2007027353 A2 WO2007027353 A2 WO 2007027353A2
Authority
WO
WIPO (PCT)
Prior art keywords
protease
substrate
reagent
test sample
color
Prior art date
Application number
PCT/US2006/030107
Other languages
English (en)
Other versions
WO2007027353A3 (fr
Inventor
Xuedong Song
Original Assignee
Kimberly-Clark Worldwide, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/217,097 external-priority patent/US7504235B2/en
Application filed by Kimberly-Clark Worldwide, Inc. filed Critical Kimberly-Clark Worldwide, Inc.
Priority to EP06789202A priority Critical patent/EP1920253A2/fr
Publication of WO2007027353A2 publication Critical patent/WO2007027353A2/fr
Publication of WO2007027353A3 publication Critical patent/WO2007027353A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/521—Single-layer analytical elements
    • G01N33/523—Single-layer analytical elements the element being adapted for a specific analyte

Definitions

  • vaginal infections include vulvovaginal candidiasis, bacterial vaginosis, and trichomoneasis. While symptomatically these infections may appear quite similar, the particular pathogenic microorganism underlying each may vary widely. For instance, candidiases are caused by pathogenic strains of yeast belonging to the genera Candida or related strains belonging mainly to the genera of Torulopsis. Trichomoneasis, on the other hand, is caused by the parasite Trichomonas vaginalis, and the underlying cause of bacterial vaginosis often cannot be attributed to one specific etiologic agent.
  • Candida albicans is the most common fungal pathogen of humans and one of the most common microorganisms isolated from blood cultures.
  • benign C. albicans may become virulent and cause infections ranging from vulvovaginal candidiasis to life-threatening disseminated candidiasis that is able to infect virtually every organ of the host.
  • pathogens causing these types of vaginal infections may vary widely, they often share common traits. For instance, many of these pathogens express common enzymes including a variety of proteases, i.e., peptidases and proteinases. Moreover, expression of particular proteases is often upregulated by the pathogenic form of the causative agent (see, e.g., Lorenz, et al., Eukaryotic Cell, 3, pp. 1076-1087 (2004)).
  • a diagnostic test kit for detecting within a test sample the presence or absence of a protease secreted by a pathogenic organism.
  • the test kit comprises a substrate that is capable of being cleaved in the presence of the protease to release a chromogenic product.
  • the substrate comprises a peptide bond.
  • the kit also includes a lateral flow device that comprises a chromatographic medium.
  • the chromatographic medium defines a detection zone within which is contained a first reagent (e.g., diazonium ion) that is capable of reacting with the chromogenic product to form a second reagent (e.g., aromatic azo compound).
  • the second reagent exhibits a color that is different than the color of the first reagent.
  • the lateral flow device also includes an absorbent material that receives the test sample after flowing through the chromatographic medium.
  • the present invention is directed to a method for detecting a protease in a test sample.
  • the method may include contacting a lateral flow device of the invention, for example, a lateral flow device such as that found in the test kits described herein, with the test sample and generating a detectable signal at the detection zone that corresponds to the presence or absence of the protease.
  • a lateral flow device of the invention for example, a lateral flow device such as that found in the test kits described herein
  • FIG. 1 is a perspective view of one embodiment of a lateral flow device that may be used in the present invention.
  • FIG. 2 is a perspective view of another embodiment of a lateral flow device that may be used in the present invention.
  • test sample generally refers to any material suspected of containing a protease.
  • the test sample may be derived from any biological source, such as a physiological fluid, including, blood, interstitial fluid, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, nasal fluid, sputum, synovial fluid, peritoneal fluid, vaginal fluid, menses, amniotic fluid, semen, and so forth.
  • physiological fluids including, blood, interstitial fluid, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, nasal fluid, sputum, synovial fluid, peritoneal fluid, vaginal fluid, menses, amniotic fluid, semen, and so forth.
  • other liquid samples may be used such as water, food products, and so forth, for the performance of environmental or food production assays.
  • a solid material suspected of containing the protease may be used as the test sample.
  • the test sample may be used directly as obtained from the biological source or following a pretreatment to modify the character of the sample.
  • pretreatment may include preparing plasma from blood, diluting viscous fluids, and so forth.
  • Methods of pretreatment may also involve filtration, precipitation, dilution, distillation, mixing, concentration, inactivation of interfering components, the addition of reagents, lysing, etc.
  • it may also be beneficial to modify a solid test sample to form a liquid medium or to release the protease.
  • protein refers to any molecular chain of amino acids that is capable of interacting structurally, enzymatically or otherwise with other proteins, polypeptides or any other organic or inorganic molecule.
  • polypeptide refers to a molecular chain of amino acids and does not refer to a specific length of the product. Thus, peptides, oligopeptides and proteins are included within the definition of polypeptide. This term is also intended to include polypeptides that have been subjected to post- expression modifications such as, for example, glycosylates, acetylations, phosphorylations, and so forth.
  • proteases refers to any of various enzymes that catalyze the hydrolytic breakdown of proteins into smaller segments, including polypeptides and/or amino acids. Accordingly, included in the definition are proteinases and peptidases.
  • proteinase refers to a protease that catalyzes the hydrolytic breakdown of proteins by splitting them into smaller peptide fractions, i.e., polypeptides or amino acids.
  • peptidase refers to a protease that catalyzes the hydrolytic breakdown of peptides via cleavage of an individual amino acid from the peptide chain.
  • the present invention is directed to a device for detecting the presence of a protease in a test sample.
  • the protease may be expressed and/or upregulated by one or more pathogens responsible for common vaginal infections, such as bacterial vaginosis, trichomoneasis, and vulvovaginal candidiasis.
  • pathogens responsible for common vaginal infections, such as bacterial vaginosis, trichomoneasis, and vulvovaginal candidiasis.
  • the expression of the detected protease may be upregulated by the pathogenic form of a Candida species (e.g., C. albicans), which may aid in the diagnosis of a yeast infection or disseminated candidiasis.
  • Proteases e.g., proline iminopeptidase
  • the technique of the present invention employs a variety of reagents for detecting the protease.
  • One such reagent is a substrate that includes a peptide bond.
  • the substrate is chemically acted upon or "cleaved" by the protease of interest to release a chromogenic product.
  • the chromogenic product thus released is capable of conversion to a secondary product that is then recognizable.
  • the released chromogenic product may react with a first reagent to form a second reagent that has a discemable color.
  • second reagents and their reaction products are further described below.
  • the substrates of the present invention can include one or more aromatic rings, in addition to the peptide bond.
  • the aromatic groups may be substituted or unsubstituted.
  • Specific examples of possible aromatic groups may include, for instance, substituted or unsubstituted 4-aminoantipyrine, tetramethylbenzine, 2,2'-azino- bis(3-ethyl-benzthiazoline-6-sulfonic) acid, and so forth.
  • the invention is directed to the detection of secreted aminoproteases.
  • the substrate may include a peptide or polypeptide that is catalytically hydrolyzed in the presence of the aminoprotease to yield an aromatic compound.
  • the aromatic substrates may include, for instance, ⁇ -naphthylamide substrates having the following general formula:
  • R1 may be a monoamino acid residue or a peptide residue
  • R2 may be a hydrogen atom or any other suitable group blocking the N-terminal end of the substrate.
  • R2 may be substituted or unsubstituted, and may be an alkyl group, an alkyoxy group, a hydroxyalkyl group, an alkylene group, a fatty acid group, and so forth.
  • the amino acid or peptide derivatized substrates are hydrolyzed by the protease.
  • a ⁇ -naphthylamide substrate may be hydrolyzed by an aminoprotease to form a ⁇ -naphthylamine, which has the following structure:
  • the monoamino acid or peptide residue of the substrate may be selected as one that is susceptible to cleavage by an aminoprotease of interest.
  • the reagents utilized in the disclosed devices may thus be selected to specifically target an protease of interest.
  • certain aminopeptidases e.g., homologs of aminopeptidase I (ScLAP4) are upregulated upon the transition of C. albicans from the benign commensal form to the pathogenic hyphal form (see, e.g., Lorenz, et al., Eukaryotic Cell, 3, pp. 1076-1087 (2004).
  • a substrate may be utilized including a residue susceptible to cleavage by one of these upregulated aminopeptidases, in order to more accurately diagnose the presence of hyphal C. albicans in a host.
  • suitable substrates for proteases include, for instance, proteins or glycoproteins, peptides, and so forth.
  • suitable substrates for peptidases and/or proteinases may include peptides, proteins, and/or glycoproteins such as casein (e.g., ⁇ -casein, azocasein, etc.), albumin (e.g., bovine serum albumin), hemoglobin, myoglobin, keratin, gelatin, insulin, proteoglycan, fibronectin, laminin, collagen, elastin, and so forth. Still other suitable substrates are described in U.S. Patent Nos.
  • the rate of the protease-catalyzed reaction may be selectively controlled using techniques known in the art, such as controlling the temperature, pH, substrate concentration, the presence of accelerators, the presence of inhibitors (competitive (binds to protease), uncompetitive (binds to protease -substrate complex), or noncompetitive (binds to protease and/or protease -substrate complex)), and so forth. These factors may be selectively controlled as desired to increase or decrease the reaction time.
  • an accelerator may be employed to enhance protease activity.
  • Suitable accelerators for hydrolytic proteases may include, for instance, pyridine, imidazole and their derivatives, metal complexes, and alcohols.
  • the pH may also be selectively controlled to enhance protease activity and to inhibit unwanted side reactions. For instance, many substrates are unstable in highly basic or highly acidic conditions due to their tendency to hydrolyze. Thus, the pH is typically maintained at a relatively neutral level, such as from about 6 to about 9, and in some embodiments, about 7.
  • Some biologically compatible buffers that may be used to maintain the desired pH include borate buffers, phosphate-buffered saline (PBS), 2-(N-morpholino) ethane sulfonic acid (“MES”), tris-hydroxymethylaminomethane (“Tris”), citrate buffers, and so forth.
  • PBS phosphate-buffered saline
  • MES 2-(N-morpholino) ethane sulfonic acid
  • Tris tris-hydroxymethylaminomethane
  • citrate buffers and so forth.
  • the released chromogenic product may be an aromatic compound that is a nucleophile in that it contains a group that is electron rich (e.g., amine) and that may form bonds with electron deficient groups.
  • ⁇ - naphthylamides may be hydrolyzed by a protease to form ⁇ -naphthylamine.
  • ⁇ - naphthylamine contains an electron-rich, aromatic ring system that is capable of undergoing electrophilic attack by a diazonium ion having the generic formula:
  • the diazonium ion may be zwitterionic in that the counterion of the diazonium moiety is covalently bound to the ring system.
  • the ring system of the diazonium ion may be substituted or unsubstituted.
  • the ion may be provided by a variety of suitable diazonium salts, such as diazonium chlorides, diazonium acid sulphates, diazonium alkyl sulphates, diazonium fluoborates, diazonium benzenesulphonates, diazonium acid 1 ,5-naphthalenedisulphonates, and so forth.
  • diazonium salts are 1-diazo-2-naphthol-4-sulfonate; 1- diazophenyl-3-carbonate; 4-diazo-3-hydroxy-1-naphthylsuIfonate (DNSA); 4-diazo- 3-hydroxy-7-nitro-1-naphthylsulfonate (NDNSA); 4-diazo-3-hydroxy-1 ,7- naphthyldisulfonate; 2-methoxy-4-(N-morpholinyl) benzene diazonium chloride; 4- diazo-3-hydroxy-7-bromo-1 -naphthylsulfonate; and 4-diazo-3-hydroxy-7- [1 ,oxopropyl]-1 -naphthylsulfonate.
  • DNSA diazo-3-hydroxy-1-naphthylsuIfonate
  • NDNSA 4-diazo- 3-hydroxy-7-nitro-1-naphthylsulf
  • One particularly desired diazonium salt is 5- chloro-2-methoxybenzenediazonium chloride, which has a yellow color and is classified under the name "Diazo Red RC" or "Fast Red RC.” More specifically, "Fast Red RC” has the following structure:
  • Suitable diazonium salts are classified by the common names "Fast Red B” and "Fast Blue B.” Still other suitable diazonium salts may be described in U.S. Patent Nos. 4,637,979 to Skiold, et al.: 4,806,423 to Hu ⁇ h. et al.; and 4,814,271 to Huql, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
  • macromolecular reagents e.g., polymers, oligomers, dendrimers, particles, etc.
  • macromolecular reagents may be particularly useful in the present invention.
  • macromolecular reagents contain at least two functionalities, i.e., a reactive moiety (e.g., diazonium ion) and a macromolecular moiety, which are covalently or noncovalently joined.
  • the macromolecular moiety may include, for instance, a polymeric moiety, such as a linear or branched, homopolymer or copolymer.
  • the polymeric moieties may be natural, synthetic, or combinations thereof.
  • natural polymeric moieties include, for instance, peptides, proteins, DNA/RNA and polysaccharides (e.g., glucose-based polymers).
  • synthetic polymeric moieties include, instance, polyacrylic acid and polyvinyl alcohols.
  • the macromolecular moiety may also be a particle (sometimes referred to as a "bead” or “microbead”).
  • Naturally occurring particles such as nuclei, mycoplasma, plasmids, plastids, mammalian cells (e.g., erythrocyte ghosts), unicellular microorganisms (e.g., bacteria), polysaccharides
  • synthetic particles may also be utilized.
  • latex microparticles that are labeled with a fluorescent or colored dye are utilized.
  • the particles are typically formed from polystyrene, butadiene styrenes, styreneacrylic-vinyl terpolymer, polymethylmethacrylate, polyethylmethacrylate, styrene-maleic anhydride copolymer, polyvinyl acetate, polyvinylpyridine, polydivinylbenzene, polybutyleneterephthalate, acrylonitrile, vinylchloride-acrylates, and so forth, or an aldehyde, carboxyl, amino, hydroxyl, or hydrazide derivative thereof.
  • the shape of the particles may generally vary.
  • the particles are spherical in shape.
  • other shapes are also contemplated by the present invention, such as plates, rods, discs, bars, tubes, irregular shapes, etc.
  • the size of the particles may also vary.
  • the average size (e.g., diameter) of the particles may range from about 0.1 nanometers to about 1 ,000 microns, in some embodiments, from about 0.1 nanometers to about 100 microns, and in some embodiments, from about 1 nanometer to about 10 microns.
  • the particle may generally be joined to a reactive moiety using any of a variety of well-known techniques.
  • covalent attachment of a particle to a substrate may be accomplished using carboxylic, amino, aldehyde, bromoacetyl, iodoacetyl, thiol, epoxy or other reactive functional groups, as well as residual free radicals and radical cations, through which a coupling reaction may be accomplished.
  • a surface functional group may also be incorporated as a functionalized co-monomer because the surface of the particle may contain a relatively high surface concentration of polar groups.
  • the particle may be capable of direct covalent bonding to a substrate without the need for further modification. It should also be understood that, besides covalent bonding, other attachment techniques, such as physical adsorption, may also be utilized in the present invention.
  • the nucleophilic aromatic compounds released by the hydrolysis of the substrate are capable of undergoing electrophilic attack by a reagent (e.g., diazonium ion).
  • a reagent e.g., diazonium ion
  • This reaction is often referred to as "coupling” and results in the formation of another reagent having a different color.
  • this reaction induces either a shift of the absorption maxima towards the red end of the spectrum (“bathochromic shift") or towards the blue end of the spectrum
  • absorption shift The type of absorption shift depends on the nature of the resulting azo molecule and whether it functions as an electron acceptor (oxidizing agent), in which a hypsochromic shift results, or whether it functions as an electron donor (reducing agent), in which a bathochromic shift results. Regardless, the absorption shift provides a color difference that is detectable, either visually or through instrumentation, to indicate the presence of protease within the test sample. For example, prior to contact with an infected test sample, the diazonium ion may be colorless or it may possess a certain color.
  • an aromatic azo compound will form that exhibits a color that is different than the initial color of the diazonium ion.
  • Exemplary aromatic azo compounds that may be formed include dimethyldiazene, diphenydiazene, 1- naphthyl-2-naphthyl diazene, 3-chlorophenyl-4-chlorophenyl diazene, methylvinyl diazene, and 2-naphthylphenyl diazene.
  • Fast Red RC (yellow)
  • ⁇ -naphylamine may react with ⁇ -naphylamine to form an aromatic azo compound that is red and has the following general structure (may be substituted or unsubstituted):
  • the chromogenic products released due to the hydrolysis of the substrate by the protease are not limited to aromatics.
  • the released chromogenic products may be any material that may be discernable following reaction with a reagent.
  • the chromogenic product may include one or more amino acids.
  • a chromogenic system that may be used when the chromogenic product includes an amino acid is described in U. S Patent No. 5,571 ,684 to Lawrence, et ah, previously incorporated by reference.
  • Such a chromogenic system may comprise an amino acid oxidase, a chromogen selected from the group consisting of guaiac, 2,2'-azino-bis(3-ethyl-benzthiazoline-6-sulfonic acid), tetramethylbenzidine, phenol, 4-aminoantipyrine and 4,5-dihydroxynaphthalene, a redox catalyst selected from the group consisting of peroxidases, iron protoporphyrin and metal ions, and oxygen.
  • this system may be illustrated as follows: amino acid + O 2 *-
  • the most appropriate reagent for any given released chromogenic product will depend at least upon the substrate specificity of the protease, the actual chromogenic product released, and the reaction conditions needed for a given test. The selection in any given case will be readily apparent to those skilled in the art.
  • the presence of the protease in a test sample may be readily detected.
  • the extent of the color change may be selectively controlled in accordance with the present invention to limit "false positives.” More specifically, a small and perhaps normal amount of protease within a test sample may hydrolyze a substrate to release a nucelophilic aromatic compound.
  • the released aromatic compound may undergo an oxidation reaction if left in air or other oxidizing environment for too great a period of time.
  • the resulting color of the oxidized compound may indicate a "false positive” or at the very least, adversely affect the ability to semi- quantitatively or quantitatively determine the presence of the protease.
  • the reaction is advantageously stopped following a desired reaction time so as to avoid generation of a false positive.
  • the present inventor has discovered a technique for reducing the problem of such "false positives.”
  • the technique requires no additional reagents, for instance to stop the reaction.
  • the desired reaction time may be achieved by selectively controlling the medium in which the reaction occurs. That is, the reaction medium is chromatographic in nature such that the protease and substrate are allowed to flow in a consistent and controllable manner. While flowing through the medium, the protease and substrate react to release chromogenic product that subsequently couples with a reagent such as a diazonium ion to form a detectable reagent, e.g., an aromatic azo compound. The aromatic azo compound is immobilized within a discrete detection region for analysis.
  • a reagent such as a diazonium ion
  • any unreacted substrate travels to the end of the reaction medium so that it is unable to adversely interfere with observance of the aromatic azo compound in the detection region.
  • the aromatic compounds that are released from the end of the reaction medium will not react with the reagents in the detection zone to generate potential false positives.
  • a lateral flow device 20 that may be formed according to the present invention will now be described in more detail.
  • the device 20 contains a chromatographic medium 23 optionally supported by a rigid support material 21.
  • the chromatographic medium 23 may be made from any of a variety of materials through which the test sample is capable of passing.
  • the chromatographic medium 23 may be a porous membrane formed from synthetic or naturally occurring materials, such as polysaccharides (e.g., cellulose materials such as paper and cellulose derivatives, such as cellulose acetate and nitrocellulose); polyether sulfone; polyethylene; nylon; polyvinylidene fluoride (PVDF); polyester; polypropylene; silica; inorganic materials, such as deactivated alumina, diatomaceous earth, MgSO 4 , or other inorganic finely divided material uniformly dispersed in a porous polymer matrix, with polymers such as vinyl chloride, vinyl chloride-propylene copolymer, and vinyl chloride-vinyl acetate copolymer; cloth, both naturally occurring (e.g., cotton) and synthetic (e.g., nylon or rayon); porous gels, such as silica gel, agarose
  • the chromatographic medium 23 is formed from nitrocellulose and/or polyether sulfone materials.
  • nitrocellulose refers to nitric acid esters of cellulose, which may be nitrocellulose alone, or a mixed ester of nitric acid and other acids, such as aliphatic carboxylic acids having from 1 to 7 carbon atoms.
  • the size and shape of the chromatographic medium 23 may generally vary as is readily recognized by those skilled in the art.
  • a porous membrane strip may have a length of from about 10 to about 100 millimeters, in some embodiments from about 20 to about 80 millimeters, and in some embodiments, from about 40 to about 60 millimeters.
  • the width of the membrane strip may also range from about 0.5 to about 20 millimeters, in some embodiments from about 1 to about 15 millimeters, and in some embodiments, from about 2 to about 10 millimeters.
  • the thickness of the membrane strip is generally small enough to allow transmission-based detection.
  • the membrane strip may have a thickness less than about 500 micrometers, in some embodiments less than about 250 micrometers, and in some embodiments, less than about 150 micrometers.
  • the support 21 carries the chromatographic medium 23.
  • the support 21 may be positioned directly adjacent to the chromatographic medium 23 as shown in Fig. 1 , or one or more intervening layers may be positioned between the chromatographic medium 23 and the support 21.
  • the support 21 may generally be formed from any material able to carry the chromatographic medium 23.
  • the support 21 may be formed from a material that is transmissive to light, such as transparent or optically diffuse (e.g., transluscent) materials.
  • it is generally desired that the support 21 is liquid- impermeable so that fluid flowing through the medium 23 does not leak through the support 21.
  • suitable materials for the support include, but are not limited to, glass; polymeric materials, such as polystyrene, polypropylene, polyester (e.g., Mylar® film), polybutadiene, polyvinylchloride, polyamide, polycarbonate, epoxides, methacrylates, and polymelamine; and so forth.
  • the support 21 is generally selected to have a certain minimum thickness. Likewise, the thickness of the support 21 is typically not so large as to adversely affect its optical properties.
  • the support 21 may have a thickness that ranges from about 100 to about 5,000 micrometers, in some embodiments from about 150 to about 2,000 micrometers, and in some embodiments, from about 250 to about 1 ,000 micrometers.
  • one suitable membrane strip having a thickness of about 125 micrometers may be obtained from Millipore Corp. of Bedford, Massachusetts under the name "SHF180UB25.”
  • the chromatographic medium 23 may be cast onto the support 21 , wherein the resulting laminate may be die-cut to the desired size and shape. Alternatively, the chromatographic medium 23 may simply be laminated to the support 21 with, for example, an adhesive.
  • a nitrocellulose or nylon porous membrane is adhered to a Mylar® film.
  • An adhesive is used to bind the porous membrane to the Mylar® film, such as a pressure-sensitive adhesive.
  • Laminate structures of this type are believed to be commercially available from Millipore Corp. of Bedford, Massachusetts. Still other examples of suitable laminate device structures are described in U.S. Patent No. 5,075,077 to Durlev. Ill, et al.. which is incorporated herein in its entirety by reference thereto for all purposes.
  • the device 20 also contains an absorbent material 28 that is positioned adjacent to the medium 23.
  • the absorbent material 28 assists in promoting capillary action and fluid flow through the medium 23.
  • the absorbent material 28 receives fluid that has migrated through the entire chromatographic medium 23 and thus draws any unreacted components away from the detection region to help reduce the likelihood of "false positives.”
  • Some suitable absorbent materials that may be used in the present invention include, but are not limited to, nitrocellulose, cellulosic materials, porous polyethylene pads, glass fiber filter paper, and so forth.
  • the absorbent material may be wet or dry prior to being incorporated into the device. Pre-wetting may facilitate capillary flow for some fluids, but is not typically required.
  • the absorbent material may be treated with a surfactant to assist the wicking process.
  • a user may directly apply the test sample to a portion of the chromatographic medium 23 through which it may then travel in the direction illustrated by arrow "L" in Fig. 1.
  • the test sample may first be applied to a sample application zone 24 that is in fluid communication with the chromatographic medium 23.
  • the sample application zone 24 may be formed on the medium 23.
  • the sample application zone 24 may be formed by a separate material, such as a pad.
  • suitable materials that may be used to form such sample pads include, but are not limited to, nitrocellulose, cellulose, porous polyethylene pads, and glass fiber filter paper.
  • the sample application zone 24 may also contain one or more pretreatment reagents, either diffusively or non-diffusively attached thereto.
  • the test sample travels from the sample application zone 24 to a reagent zone 22 that is in communication with the sample application zone 24.
  • the reagent zone 22 may be formed on the medium 23.
  • the reagent zone 22 is formed from a separate material or pad.
  • Such a reagent pad may be formed from any material through which the test sample is capable of passing, such as glass fibers.
  • a substrate is employed.
  • the substrate may be mixed with the test sample prior to application to the device 20.
  • the substrate may be diffusively immobilized on the device 20 prior to application of the test sample.
  • Such pre-application provides a variety of benefits, including the elimination of the need for a subsequent user to handle and mix the reagents with the test sample or a diluent. This is particularly useful in point-of- care applications when the user is not generally a trained lab technician or medical professional.
  • the substrate may be disposed downstream from the sample application zone 24. In this manner, the test sample is capable of mixing with the substrate upon application. Alternatively, the substrate may be positioned upstream from the sample application zone 24. For instance, a diluent may be employed to induce mixing between the substrate and test sample.
  • the pH may be maintained at a relatively neutral level to facilitate the desired protease-catalyzed reaction, such as described above.
  • a buffer may be mixed with the substrate prior to application to the device 20, mixed with the test sample, or both.
  • the buffer may be separately applied to the lateral flow device 20 so that it is capable of mixing with the reagents upon application to the test sample.
  • the lateral flow device 20 includes a detection zone 31 within which is immobilized a second reagent, such as a diazonium ion described above.
  • a second reagent such as a diazonium ion described above.
  • the diazonium ion may be applied directly to the medium 23 or first formed into a solution prior to application.
  • Various solvents may be utilized to form the solution, such as, but not limited to, acetonitrile, dimethylsulfoxide (DMSO), ethyl alcohol, dimethylformamide (DMF), and other polar organic solvents.
  • the amount of a diazonium salt in the solution may range from about 0.001 to about 100 milligrams per milliliter of solvent, and in some embodiments, from about 0.1 to about 10 milligrams per milliliter of solvent.
  • the detection zone 31 is defined by the chromatographic medium 23 and formed by coating a solution thereon using well- known techniques and then dried. The diazonium ion concentration may be selectively controlled to provide the desired level of detection sensitivity.
  • the diazonium ion be applied in a manner so that it does not substantially diffuse through the matrix of the chromatographic medium 23 (i.e., non-diffusively immobilized).
  • This enables a user to readily detect the change in color that occurs upon reaction of the diazonium ion with a nucleophilic aromatic compound.
  • the diazonium ion may form an ionic and/or covalent bond with functional groups present on the surface of the chromatographic medium 23 so that it remains immobilized thereon. For instance, particles, such as described herein, may facilitate the immobilization of the diazonium ion at the detection zone 31.
  • the diazonium ion may be coated onto particles, which are then immobilized on the chromatographic medium 23 of the device 20. In this manner, the diazonium ion is able to readily contact nucleophilic aromatic compounds flowing through the medium 23.
  • the lateral flow device may include a plurality of substrates, each of which may be susceptible to cleavage by a different protease.
  • the lateral flow device may be designed to examine a single test sample for more than one protease so as to identify a pathogen in the test sample with more particularity.
  • the lateral flow device 30 employs a first substrate susceptible to cleavage by a first protease, e.g., an aminopeptidase.
  • the lateral flow device also includes a first detection zone 31 , as described above, and within which is immobilized a first reagent that may interact with the cleaved chromogenic product released by the aminopeptidase.
  • the lateral flow device of Fig. 2 may employ a second substrate susceptible to cleavage by a second protease, e.g., a second aminopeptidase, an aminoproteinase, etc.
  • the second substrate may be mixed with the test sample prior to application to the device or the second substrate may be diffusively immobilized on the device either upstream or down stream of the first detection zone 31 prior to application of the test sample.
  • the lateral flow device may also include a second detection zone 36. Within the second detection zone 36 may be immobilized a second reagent that may interact with the chromogenic product released by the second protease of interest.
  • the first and second reagents may be selected to be particular to the first and second chromogenic cleavage products, respectively, so as to prevent any cross reaction.
  • the first reagent, immobilized in detection zone 31 will not interact with the second chromogenic product to produce a detectable color change
  • the second reagent, immobilized in detection zone 36 will not interact with the first chromogenic product to produce a detectable color change in detection zone 31.
  • the first detection system may be an aromatic azo system and the second detection system may be an amino acid oxidase detection system.
  • a positive result at first detection zone 31 may indicate the presence in the test sample of the first protease
  • a positive result at second detection zone 36 may indicate the presence of the second protease.
  • the combination of results may be utilized to identify the pathogen in the test sample with more particularity.
  • One benefit of the lateral flow device of the present invention is the ability to readily incorporate one or more additional reagent zones to facilitate the above-described protease-catalyzed reaction.
  • one such zone is a quenching zone 35.
  • the quenching zone 35 is configured to remove compounds from the test sample that would otherwise interfere with the accuracy of the detection system.
  • the quenching zone 35 may contain a quenching agent, such as a diazonium ion, that is capable of reacting with the reaction contaminants.
  • the quenching agent may be the same or different than the detection agent used within the detection zone 31.
  • the quenching agent is non-diffusively immobilized within the quenching zone 35 in the manner described above so that it does not flow through the medium 23 and interfere with testing.
  • the location of the quenching zone 35 may vary, but is typically positioned upstream from the detection zone 31 and the location at which the substrate is applied to avoid interference with protease detection.
  • the quenching zone 35 is positioned between the sample application zone 24 and the reagent zone 22.
  • the quenching zone 35 may be positioned upstream from the sample application zone 24.
  • Another zone that may be employed in the lateral flow device 20 for improving detection accuracy is a control zone 32.
  • the control zone 32 gives a signal to the user that the test is performing properly. More specifically, control reagents may be employed that flow through the chromatographic medium 23 upon contact with a sufficient volume of the test sample.
  • control reagents may then be observed, either visually or with an instrument, within the control zone 32.
  • the control reagents generally contain a detectable substance, such as luminescent compounds (e.g., fluorescent, phosphorescent, etc.); radioactive compounds; visual compounds (e.g., colored dye or metallic substance, such as gold); liposomes or other vesicles containing signal-producing substances; enzymes and/or substrates, and so forth.
  • a detectable substance such as luminescent compounds (e.g., fluorescent, phosphorescent, etc.); radioactive compounds; visual compounds (e.g., colored dye or metallic substance, such as gold); liposomes or other vesicles containing signal-producing substances; enzymes and/or substrates, and so forth.
  • Other suitable detectable substances may be described in U.S. Patent Nos. 5,670,381 to Jou, et al. and 5,252,459 to Tarcha, et al., which are incorporated herein in their entirety by
  • the detectable substances may be disposed on particles (sometimes referred to as “beads” or “microbeads”), such as described above.
  • the particles enhance the ability of the detectable substance to travel through a chromatographic medium.
  • suitable particles include fluorescent carboxylated microspheres sold by Molecular Probes, Inc. under the trade names “FluoSphere” (Red 580/605) and
  • control zone 32 may vary based on the nature of the test being performed.
  • the control zone 32 is defined by the chromatographic medium 23 and positioned downstream from the detection zone 31.
  • the control zone 32 may contain a material that is non-diffusively immobilized in the manner described above and forms a chemical and/or physical bond with the control reagents.
  • control zone 32 may include a polyelectrolyte that binds to the particles.
  • a polyelectrolyte that binds to the particles.
  • Various polyelectrolytic binding systems are described, for instance, in U.S. Patent App. Publication No. 2003/0124739 to Song, et al., which is incorporated herein in it entirety by reference thereto for all purposes.
  • the control zone 32 may simply be defined by a region of the absorbent material 28 to which the control reagents flow after traversing through the chromatographic medium 23.
  • the application of a sufficient volume of the test sample to the device 20 will cause a detectable signal to form within the control zone 32, whether or not the protease is present.
  • a control zone is that the user is informed that a sufficient volume of test sample has been added without requiring careful measurement or calculation. This provides the ability to use the lateral flow device 20 without the need for externally controlling the reaction time, test sample volume, etc.
  • the lateral flow device 20 may also include other optional zones.
  • the lateral flow device 20 may include an accelerator zone (not shown) in which is contained an accelerator for the protease-catalyzed substrate reaction.
  • the accelerator is diffusively immobilized within the accelerator zone in the manner described above so that it may flow through the medium 23 upon contact with the test sample.
  • the location of the accelerator zone may generally vary, so long as it positioned upstream from the detection zone 31.
  • the accelerator zone may be positioned at a location (e.g., sample application zone 24) that is upstream from the application of the substrate (e.g., reagent zone 24). Due to the separation provided between the substrate and accelerator, the likelihood of any premature reaction therebetween is thus reduced.
  • the detection zone 31 , quenching zone 35, control zone 32, accelerator zone, and any other zone employed in the lateral flow device 20 may generally provide any number of distinct detection regions so that a user may better determine the concentration of the protease within the test sample.
  • Each region may contain the same or different materials.
  • the zones may include two or more distinct regions (e.g., lines, dots, etc.).
  • the regions may be disposed in the form of lines in a direction that is substantially perpendicular to the flow of the test sample through the device 20.
  • the regions may be disposed in the form of lines in a direction that is substantially parallel to the flow of the test sample through the device 20.
  • a test sample containing an aminopeptidase is applied to the sample application zone 24 and travels in the direction "L" to the reagent zone 22.
  • the aminopeptidase is able to mix with and begin to initiate the catalytic reaction.
  • the aminopeptidase hydrolyzes the peptide bonds of the substrate and releases chromogenic products, such as nucleophilic aromatic compounds.
  • the aromatic compounds then flow to the detection zone 31 where they react with a diazonium ion to form a colored azo compound.
  • the detection zone 31 changes color.
  • the color or color intensity of the detection zone 31 may be determined, either visually or with instrumentation. If desired, the intensity of the color at the detection zone 31 may be measured to quantitatively or semi- quantitatively determine the level of the aminopeptidase present in the test sample.
  • the intensity of the color at the detection zone 31 is typically directly proportional to protease concentration.
  • the intensity of the detection signal "l s " produced at the detection zone 31 may also be compared to a predetermined detection curve developed for a plurality of known protease concentrations. To determine the quantity of protease in an unknown test sample, the signal may simply be converted to protease concentration according to the detection curve.
  • the protease e.g., the aminopeptidase
  • any unreacted substrate and/or aromatic compounds then travel past the detection zone 31 until they reach the absorbent material 28.
  • the aromatic compounds will oxidize over a period of time in air to form colored compounds.
  • such colored compounds are not located at the detection region 31 , they generally do not interfere with the detection accuracy.
  • the present invention provides a relatively simple, compact and cost- efficient device for accurately detecting the presence of protease within a test sample (e.g., vaginal fluid).
  • the test result may be visible so that it is readily observed by the person performing the test in a prompt manner and under test conditions conducive to highly reliable and consistent test results.
  • the test is also less time-dependent. Accordingly, the present invention may provide a convenient, accurate determination of the presence of a pathogenic agent in the source of the test sample.
  • the present invention may be better understood with reference to the following example.
  • a cellulose pad was laminated to the one end of the membrane card to provide an absorbent or wicking pad.
  • a reagent pad was fabricated from a glass fiber pad having a length of 15 centimeters (Millipore Inc.). More specifically, the pad was soaked with 15 milliliters of a mixture containing (i) 1 wt.% Tween 20 (available from Sigma-Aldrich
  • the aminopeptidase was derived from Streptomyces griseus and obtained from Sigma. 150 microliters of each sample were then applied to the sample application zone of two separate devices. After approximately 15 minutes, each sample was visually observed. For the control sample, the detection zone remained yellow; however, for the positive aminopeptidase sample, the detection zone was red.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention a trait à une trousse d'essai diagnostique pour la détection de la présence ou de l'absence d'une protéase (par exemple, l'aminopeptidase) au sein d'un échantillon d'essai. La trousse d'essai comporte un substrat qui est capable d'être clivé en présence de la protéase pour la libération d'un composé. La trousse comporte également un dispositif d'écoulement latéral comprenant un support chromatographique. Le support chromatographique définit une zone de détection au sein de laquelle est contenu un premier réactif (par exemple, l'ion diazonium) qui est capable de réagir avec le composé pour former un deuxième réactif (par exemple, un composé azoïque aromatique). Le deuxième réactif présente une couleur qui est différente de la couleur du premier réactif. Le dispositif d'écoulement latéral comporte également un matériau absorbant disposé adjacent au support chromatographique, le matériau absorbant recevant l'échantillon d'essai suite à son écoulement à travers le support chromatographique.
PCT/US2006/030107 2005-08-31 2006-08-01 Detection de proteases secretees a partir de micro-organismes pathogenes WO2007027353A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06789202A EP1920253A2 (fr) 2005-08-31 2006-08-01 Detection de proteases secretees a partir de micro-organismes pathogenes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/217,097 2005-08-31
US11/217,097 US7504235B2 (en) 2005-08-31 2005-08-31 Enzyme detection technique
US11/364,810 US7575887B2 (en) 2005-08-31 2006-02-28 Detection of proteases secreted from pathogenic microorganisms
US11/364,810 2006-02-28

Publications (2)

Publication Number Publication Date
WO2007027353A2 true WO2007027353A2 (fr) 2007-03-08
WO2007027353A3 WO2007027353A3 (fr) 2007-06-07

Family

ID=37809345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/030107 WO2007027353A2 (fr) 2005-08-31 2006-08-01 Detection de proteases secretees a partir de micro-organismes pathogenes

Country Status (2)

Country Link
EP (1) EP1920253A2 (fr)
WO (1) WO2007027353A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027234A2 (fr) * 2005-08-31 2007-03-08 Kimberly-Clark Worldwide, Inc. Technique de detection d'enzymes
WO2008075216A1 (fr) * 2006-12-15 2008-06-26 Kimberly-Clark Worldwide, Inc. Immobilisation d'indicateur sur des dispositifs d'essai
WO2008132620A2 (fr) * 2007-04-30 2008-11-06 Kimberly-Clark Worldwide, Inc. Dispositif à écoulement latéral pour une fixation à un article absorbant

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806423A (en) * 1984-04-06 1989-02-21 Miles Inc. Agents and process for the detection of esterolytic and/or proteolytic enzymes
US5571684A (en) * 1994-11-07 1996-11-05 Litmus Concepts, Inc. Assay for proline iminopeptidase and other hydrolytic activities
WO2005057214A1 (fr) * 2003-11-21 2005-06-23 Kimberly-Clark Worldwide, Inc. Elargissement de la plage de detection dynamique de dispositifs d'analyse
WO2005098020A1 (fr) * 2004-04-01 2005-10-20 Binax, Inc. Methode de dosage permettant de determiner la quantite de neutrophiles de la muqueuse chez les patients atteints de neutropenie
WO2007027234A2 (fr) * 2005-08-31 2007-03-08 Kimberly-Clark Worldwide, Inc. Technique de detection d'enzymes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306642B1 (en) * 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US7521226B2 (en) * 2004-06-30 2009-04-21 Kimberly-Clark Worldwide, Inc. One-step enzymatic and amine detection technique
US7906276B2 (en) * 2004-06-30 2011-03-15 Kimberly-Clark Worldwide, Inc. Enzymatic detection techniques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806423A (en) * 1984-04-06 1989-02-21 Miles Inc. Agents and process for the detection of esterolytic and/or proteolytic enzymes
US5571684A (en) * 1994-11-07 1996-11-05 Litmus Concepts, Inc. Assay for proline iminopeptidase and other hydrolytic activities
WO2005057214A1 (fr) * 2003-11-21 2005-06-23 Kimberly-Clark Worldwide, Inc. Elargissement de la plage de detection dynamique de dispositifs d'analyse
WO2005098020A1 (fr) * 2004-04-01 2005-10-20 Binax, Inc. Methode de dosage permettant de determiner la quantite de neutrophiles de la muqueuse chez les patients atteints de neutropenie
WO2007027234A2 (fr) * 2005-08-31 2007-03-08 Kimberly-Clark Worldwide, Inc. Technique de detection d'enzymes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1920253A2 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027234A2 (fr) * 2005-08-31 2007-03-08 Kimberly-Clark Worldwide, Inc. Technique de detection d'enzymes
WO2007027234A3 (fr) * 2005-08-31 2007-06-07 Kimberly Clark Co Technique de detection d'enzymes
WO2008075216A1 (fr) * 2006-12-15 2008-06-26 Kimberly-Clark Worldwide, Inc. Immobilisation d'indicateur sur des dispositifs d'essai
US7935538B2 (en) 2006-12-15 2011-05-03 Kimberly-Clark Worldwide, Inc. Indicator immobilization on assay devices
WO2008132620A2 (fr) * 2007-04-30 2008-11-06 Kimberly-Clark Worldwide, Inc. Dispositif à écoulement latéral pour une fixation à un article absorbant
WO2008132620A3 (fr) * 2007-04-30 2008-12-31 Kimberly Clark Co Dispositif à écoulement latéral pour une fixation à un article absorbant
AU2008243894B2 (en) * 2007-04-30 2013-03-21 Kimberly-Clark Worldwide, Inc. Lateral flow device for attachment to an absorbent article
US9895094B2 (en) 2007-04-30 2018-02-20 Kimberly-Clark Worldwide, Inc. Lateral flow device for attachment to an absorbent article

Also Published As

Publication number Publication date
EP1920253A2 (fr) 2008-05-14
WO2007027353A3 (fr) 2007-06-07

Similar Documents

Publication Publication Date Title
US8609401B2 (en) Detection of proteases secreted from a pathogenic microorganisms
US7291481B2 (en) Assays for trichomonal and other hydrolases
EP1920251B1 (fr) Technique de détection des nitrites
US7964340B2 (en) One-step enzymatic and amine detection technique
KR101470666B1 (ko) 흡수 용품에 부착하기 위한 측방 흐름 디바이스
US7897360B2 (en) Enzyme detection techniques
US20110129823A1 (en) Enzymatic Detection Techniques
US8758989B2 (en) Enzymatic detection techniques
EP1920253A2 (fr) Detection de proteases secretees a partir de micro-organismes pathogenes
CN109900889A (zh) 一种自动滤血干式光化学法微通道肝功三项检测卡
JP2022529552A (ja) 体液及び創傷関連生体分子の分析システム
US20180321202A1 (en) Methods and devices for detecting methanol poisoning using formate oxidase
WO2018203145A1 (fr) Systèmes et procédés pour surveiller des liquides biologiques
CN113866426A (zh) 一种检测d-二聚体的试剂盒及其制备方法
GB2494934A (en) Wound prognosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006789202

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE